Gal Wald, MD

Gal Wald, MD, highlights patient-reported outcomes from a phase 2 trial of intravesical gemcitabine plus BCG for patients with BCG-exposed high-grade NMIBC.

"Overall, our trial shows promising early oncological efficacy with a favorable toxicity profile," says Gal Wald, MD.

"Combination therapies have now become the forefront of our field, and we are trying to do better to avoid BCG-unresponsive disease, as well as progression to either muscle-invasive or metastatic disease," says Gal Wald, MD.